Company intelligence / Profile preview

Detect

Guilford, Connecticut, United States

Ownership: Private
Employees: ~300
Development stage: Other

Overview

Detect developed and received FDA emergency use authorization for a molecular, PCR-quality at-home Covid-19 test and is expanding its platform technology toward other infectious and women's health indications. The at-home test delivers results in about one hour with clinical performance comparable to lab-based PCR testing. NIH RADx initiative provided significant non-dilutive funding to scale manufacturing and expand the test menu.

Therapeutic areas: Women's HealthInfectious Diseases
Modalities: DeviceMolecular diagnostic platform
Industry: Molecular Diagnostics

Partnerships

National Institutes of Health (NIH)—RADx initiative

Beyond the preview

Go deeper on Detect.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Detect.

Explore the full profile